Science & Enterprise subscription

Follow us on Twitter

  • Make me wanna shout ... #BillsMafia https://t.co/iF1vhKHXtu
    about 1 hour ago
  • First of two podcasts with experiences of news photographers in the insurrection. Thanks @cherissmay for sharing yo… https://t.co/aCjPD6ct84
    about 17 hours ago
  • Half or more of American adults express negative opinions about the way Covid-19 vaccines are distributed, accordin… https://t.co/9l2SUpW85u
    about 23 hours ago
  • New post on Science and Enterprise: Infographic – US Public Down on Vaccine Rollout https://t.co/vegz3ihvIO #Science #Business
    about 23 hours ago
  • We've written several times about Lander and his work, including companies he founded. ... Biden to Elevate Science… https://t.co/rWVGTa1gPL
    about 1 day ago

Please share Science & Enterprise

Infographic – US Public Down on Vaccine Rollout

Chart: Vaccine rollout opinions

Half or more of American adults express negative opinions about the way Covid-19 vaccines are distributed, according to a recent survey. . . . → Read More: Infographic – US Public Down on Vaccine Rollout

Biotech Licenses mRNA Technology for Aging

Hands of older person

A biotechnology enterprise is licensing research from Stanford University on messenger RNA to produce proteins that rejuvenate cells damaged by aging. . . . → Read More: Biotech Licenses mRNA Technology for Aging

US Govt to Buy 1.25M Regeneron Covid-19 Therapies

SARS-Cov-2 virus

The U.S. Department of Health and Human Services is buying up to 1.25 million more doses of Regeneron’s Covid-19 antibody therapy, for $2.63 billion. . . . → Read More: US Govt to Buy 1.25M Regeneron Covid-19 Therapies

Drug Maker Gains Access to Hidden Protein Immunotherapies

T-cells and cancer cells

Global drug maker Boehringer Ingelheim is gaining access to an immunotherapy technology that targets usually hidden proteins to attack cancer cells. . . . → Read More: Drug Maker Gains Access to Hidden Protein Immunotherapies

Moderna Developing Flu, HIV, Nipah Vaccines

Syringe and three vials

Moderna Inc., developer of a currently authorized Covid-19 vaccine, is expanding its vaccine pipeline to cover three more common infectious viral diseases. . . . → Read More: Moderna Developing Flu, HIV, Nipah Vaccines

Drug Price Disruptor Biotech Raises $500M in New Funds

Pills and dollar bill

A start-up biotechnology company that aims to bring drugs to market at lower cost is raising $500 million in its second venture funding round. . . . → Read More: Drug Price Disruptor Biotech Raises $500M in New Funds

Infographic – Countries Making Covid-19 Vaccines

Chart: Covid-19 vaccine sites

The U.S. and India are set to produce two-thirds of the world’s Covid-19 vaccine doses by the end of this year, presenting worldwide distribution challenges. . . . → Read More: Infographic – Countries Making Covid-19 Vaccines

Vaccine Shown Active Against New Covid-19 Variants

mRNA vaccine graphic

A current Covid-19 vaccine is shown in lab tests to produce antibodies that appear to protect against new mutations found in South Africa and the U.K. . . . → Read More: Vaccine Shown Active Against New Covid-19 Variants

CureVac, Bayer Partner on Covid-19 Vaccine Supply

Syringe in hand

Vaccine developer CureVac and global drug maker Bayer are partnering on further development, authorization, and supply of CureVac’s Covid-19 vaccine. . . . → Read More: CureVac, Bayer Partner on Covid-19 Vaccine Supply

Synthetic Biology Company Raises $105M in New Funds

DNA chip graphic

A company developing cellular and genetic therapies for cancer designed like electronic circuits is raising $105 million in its second venture round. . . . → Read More: Synthetic Biology Company Raises $105M in New Funds